Using multiparameter flow cytometry, a CD19⁺CD45^low blast cell gating strategy allowed to monitor blast population and HER2-positive expression after trastuzumab infusions. In this example of patient 1, HER2 expression became quasi-undetectable in bone marrow after 12 trastuzumab infusions.